2025 Q4 -tulosraportti
Vain PDF
19 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 339 | - | - | ||
| 205 | - | - | ||
| 35 | - | - | ||
| 36 | - | - | ||
| 20 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13 t sittenShort rises Thursday 1.12 % Friday 1.24 % today 1.39 %
·10 t sittenIt's brewing for a good rise when a price-driving pm comes!
·6 t sitten · MuokattuIt probably depends on whether the first thing that comes is a rejection in Mexico :-). I think the sequence for the next 12mdr could be: 1) Q1'26, where cashburn might slowly start to rise 2) a decision in Mexico 3) progress in clinical phase (own or partner), coinciding with 5) if partner 4) Q2'26, where cashburn might slowly start to rise 5) first partner milestone 6) second partner milestone 7) new agreement/deal The question is somewhat how much effect the Q-reports will have, when there are now so many investors who haven't really analyzed the case (currently I have only seen something from Redeye), but solely invest based on gut feelings that the price probably should be 30+ with cash balance, 2 agreements (thereof 1 pre-clinical) and 3 projects in pre-clinical phase, and one starts to see the cash balance dwindling faster than expected. I am ready on the buy button below 15 :-) - it was close again today.- ·11.3.Aktieinfo has just made a new analysis of saniona interesting reading
·12.3.Jump in and out as you wish. I'm holding mine until exit, I believe there's significantly more value there than trying to trade the stock.·12.3. · MuokattuBuy and hold is generally clearly the best strategy for any stock, but I believe in - so I think it sounds like a good plan :-) And I agree that Saniona is not a stock one should “Trade” - for me, the position is part of my overall portfolio - and since I don't have unlimited funds, I continuously try to weigh the risk/reward potential of the different positions - and there I might choose to move things around sometimes. - 9.3.9.3.Short 1,26 %
·9.3.As I said, I think it's lagging. BUT you're welcome to be right because it means they've increased their position but haven't managed to push down the price anywhere near what they've done on previous days. For me, that signals that we're starting to approach the end of the road in that case.·9.3. · MuokattuI also just got a funny idea. In their analysis in Sep'25 and Nov'25, Redeye has an rNPV calculation with 7, 19 and 35 in Bear, Base, Bull. I just combined those with LoA according to statistical percentages from my 37-page ChatGPT document. Redeye's rNPV without LoA adjustment hits 133 = their rNPV if EVERYTHING goes through (100% LoA on all projects). If I set them to statistical averages of 17.5 for Phase I (14/15) and 3% for preclinical (3-14) - and at the same time Tesofensine to 0 (85) and Tesomet to 50 (33) then I end up at 12.7 - not entirely off compared to my mentioned window of 12-15 back from 23/12. Redeye incidentally only values 100% LoA on Tesofensine at 1.25/share - so according to them, it's almost irrelevant whether they get that approval or not. So I'm becoming more and more convinced that 12-15 is a fair price right now - and I think something more needs to happen before the 20s are "Fair value". But the market can, of course, think something else - and in the end, it is the market that is "right".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
19 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenShort rises Thursday 1.12 % Friday 1.24 % today 1.39 %·10 t sittenIt's brewing for a good rise when a price-driving pm comes!·6 t sitten · MuokattuIt probably depends on whether the first thing that comes is a rejection in Mexico :-). I think the sequence for the next 12mdr could be: 1) Q1'26, where cashburn might slowly start to rise 2) a decision in Mexico 3) progress in clinical phase (own or partner), coinciding with 5) if partner 4) Q2'26, where cashburn might slowly start to rise 5) first partner milestone 6) second partner milestone 7) new agreement/deal The question is somewhat how much effect the Q-reports will have, when there are now so many investors who haven't really analyzed the case (currently I have only seen something from Redeye), but solely invest based on gut feelings that the price probably should be 30+ with cash balance, 2 agreements (thereof 1 pre-clinical) and 3 projects in pre-clinical phase, and one starts to see the cash balance dwindling faster than expected. I am ready on the buy button below 15 :-) - it was close again today.
- ·11.3.Aktieinfo has just made a new analysis of saniona interesting reading·12.3.Jump in and out as you wish. I'm holding mine until exit, I believe there's significantly more value there than trying to trade the stock.·12.3. · MuokattuBuy and hold is generally clearly the best strategy for any stock, but I believe in - so I think it sounds like a good plan :-) And I agree that Saniona is not a stock one should “Trade” - for me, the position is part of my overall portfolio - and since I don't have unlimited funds, I continuously try to weigh the risk/reward potential of the different positions - and there I might choose to move things around sometimes.
- 9.3.9.3.Short 1,26 %·9.3.As I said, I think it's lagging. BUT you're welcome to be right because it means they've increased their position but haven't managed to push down the price anywhere near what they've done on previous days. For me, that signals that we're starting to approach the end of the road in that case.·9.3. · MuokattuI also just got a funny idea. In their analysis in Sep'25 and Nov'25, Redeye has an rNPV calculation with 7, 19 and 35 in Bear, Base, Bull. I just combined those with LoA according to statistical percentages from my 37-page ChatGPT document. Redeye's rNPV without LoA adjustment hits 133 = their rNPV if EVERYTHING goes through (100% LoA on all projects). If I set them to statistical averages of 17.5 for Phase I (14/15) and 3% for preclinical (3-14) - and at the same time Tesofensine to 0 (85) and Tesomet to 50 (33) then I end up at 12.7 - not entirely off compared to my mentioned window of 12-15 back from 23/12. Redeye incidentally only values 100% LoA on Tesofensine at 1.25/share - so according to them, it's almost irrelevant whether they get that approval or not. So I'm becoming more and more convinced that 12-15 is a fair price right now - and I think something more needs to happen before the 20s are "Fair value". But the market can, of course, think something else - and in the end, it is the market that is "right".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 339 | - | - | ||
| 205 | - | - | ||
| 35 | - | - | ||
| 36 | - | - | ||
| 20 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
19 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sittenShort rises Thursday 1.12 % Friday 1.24 % today 1.39 %·10 t sittenIt's brewing for a good rise when a price-driving pm comes!·6 t sitten · MuokattuIt probably depends on whether the first thing that comes is a rejection in Mexico :-). I think the sequence for the next 12mdr could be: 1) Q1'26, where cashburn might slowly start to rise 2) a decision in Mexico 3) progress in clinical phase (own or partner), coinciding with 5) if partner 4) Q2'26, where cashburn might slowly start to rise 5) first partner milestone 6) second partner milestone 7) new agreement/deal The question is somewhat how much effect the Q-reports will have, when there are now so many investors who haven't really analyzed the case (currently I have only seen something from Redeye), but solely invest based on gut feelings that the price probably should be 30+ with cash balance, 2 agreements (thereof 1 pre-clinical) and 3 projects in pre-clinical phase, and one starts to see the cash balance dwindling faster than expected. I am ready on the buy button below 15 :-) - it was close again today.
- ·11.3.Aktieinfo has just made a new analysis of saniona interesting reading·12.3.Jump in and out as you wish. I'm holding mine until exit, I believe there's significantly more value there than trying to trade the stock.·12.3. · MuokattuBuy and hold is generally clearly the best strategy for any stock, but I believe in - so I think it sounds like a good plan :-) And I agree that Saniona is not a stock one should “Trade” - for me, the position is part of my overall portfolio - and since I don't have unlimited funds, I continuously try to weigh the risk/reward potential of the different positions - and there I might choose to move things around sometimes.
- 9.3.9.3.Short 1,26 %·9.3.As I said, I think it's lagging. BUT you're welcome to be right because it means they've increased their position but haven't managed to push down the price anywhere near what they've done on previous days. For me, that signals that we're starting to approach the end of the road in that case.·9.3. · MuokattuI also just got a funny idea. In their analysis in Sep'25 and Nov'25, Redeye has an rNPV calculation with 7, 19 and 35 in Bear, Base, Bull. I just combined those with LoA according to statistical percentages from my 37-page ChatGPT document. Redeye's rNPV without LoA adjustment hits 133 = their rNPV if EVERYTHING goes through (100% LoA on all projects). If I set them to statistical averages of 17.5 for Phase I (14/15) and 3% for preclinical (3-14) - and at the same time Tesofensine to 0 (85) and Tesomet to 50 (33) then I end up at 12.7 - not entirely off compared to my mentioned window of 12-15 back from 23/12. Redeye incidentally only values 100% LoA on Tesofensine at 1.25/share - so according to them, it's almost irrelevant whether they get that approval or not. So I'm becoming more and more convinced that 12-15 is a fair price right now - and I think something more needs to happen before the 20s are "Fair value". But the market can, of course, think something else - and in the end, it is the market that is "right".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 339 | - | - | ||
| 205 | - | - | ||
| 35 | - | - | ||
| 36 | - | - | ||
| 20 | - | - |
Välittäjätilasto
Dataa ei löytynyt